No Detail Found!

Defcient Mismatch Repair and Lymphocytic Response to Tumor as Prognostic Markers in Stage II Colon Cancer Patients

Author(s)
Murat Sari Department of Medical Oncology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Elif Atag Department of Medical Oncology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Tarik Demir Department of Medical Oncology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Eda Tanrikulu Simsek Department of Medical Oncology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Ezgi Coban Department of Medical Oncology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Makbule Cikrikcioglu Department of Pathology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey
Abstract
Objective: To investigate the relationship between colon cancer (CC) subtypes de ned by the status of tumor-in ltrating lymphocytes (TIL) and mismatch repair (MMR) combination with clinicopathological features and survival. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, Haydarpa_a Numune Research and Training Hospital, Istanbul, Turkey, from July 2010 to March 2020. Methodology: Eighty-three patients with operated stage II colon cancer were included in the study. Pathology, surgery and oncological treatment and follow-up information were obtained from patient les; and statistical analyses were performed on overall survival (OS). Tumor-in ltrating lymphocytes and mismatch repair status was determined with the help of immunohistochemistry. Results: TIL-high and de cient MMR (dMMR) status were detected in 26 patients (31.3%) and 21 patients (25.3%), respectively. Tumors were divided into four subgroups according to TIL and MMR status. TIL-high/dMMR tumors had the most favourable prognosis, while TIL-low/pro cient MMR tumors exhibited poor OS. Conclusion: The combination of TIL and MMR could enable us to di erentiate patients' survival outcomes in more details. Therefore, considering that the TIL and MMR status, evaluated by IHC, may be a cost-e ective and e ective option for risk classi cation in patients with stage II colon cancer.
Publication Details
Page(s) 186-192
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Prognosis, Mismatch repair, Lymphocytic response, Tumor-infiltrating lymphocytes, Stage II cancer, Colon cancer.
0

Citations

0

Downloads

77

Views